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Background: Fragile X syndrome (FXS) is the leading cause of inheritable intellectual disability in male children,
and is predominantly caused by a single gene mutation resulting in expanded trinucleotide CGG-repeats within
the 5’ untranslated region of the fragile X mental retardation (FMR1) gene. Reports have suggested the presence of
immune dysregulation in FXS with evidence of altered plasma cytokine levels; however, no studies have directly
assessed functional cellular immune responses in children with FXS. In order to ascertain if immune dysregulation is
present in children with FXS, dynamic cellular responses to immune stimulation were examined.
Methods: Peripheral blood mononuclear cells (PBMC) were from male children with FXS (n = 27) and from male
aged-matched typically developing (TD) controls (n = 8). PBMC were cultured for 48 hours in media alone or
with lipopolysaccharides (LPS; 1 μg/mL) to stimulate the innate immune response or with phytohemagglutinin
(PHA; 8 μg/mL) to stimulate the adaptive T-cell response. Additionally, the group I mGluR agonist, DHPG, was
added to cultures to ascertain the role of mGluR signaling in the immune response in subject with FXS. Supernatants
were harvested and cytokine levels were assessed using Luminex multiplexing technology.
Results: Children with FXS displayed similar innate immune response following challenge with LPS alone when
compared with TD controls; however, when LPS was added in the presence of a group I mGluR agonist, DHPG,
increased immune response were observed in children with FXS for a number of pro-inflammatory cytokines including
IL-6 (P = 0.02), and IL-12p40 (P < 0.01). Following PHA stimulation, with or without DHPG, no significant differences
between subjects with FXS and TD were seen.
Conclusions: In unstimulated cultures, subjects with FXS did not display altered dynamic immune response to LPS
or PHA alone; however, subjects with FXS showed an altered response to co-current stimulation of LPS and DHPG,
such that subjects with FXS failed to inhibit production of pro-inflammatory cytokines, suggesting a role of group I
mGluR signaling in innate immune responses in FXS.
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Fragile X syndrome (FXS) is a single-gene disorder
nearly always caused by an unstable mutation in the fra-
gile X mental retardation 1 (FMR1) X-linked gene and
results from the expansion of a trinucleotide (CGG) re-
peat sequence in the 5’UTR of this gene [1]. The full
mutation, present in individuals having an FMR1 allele
with more than 200 CGG repeats, typically is methylated
with partial or complete transcriptional silencing of the
FMR1 gene, leading to a reduction or absence of the
FMR1 protein, FMRP [1-4]. Although FXS is associated
with a characteristic phenotype, there is considerable
within-syndrome variation in the severity of affectedness
and the profile of impairments including a significant
(approximately 30%) comorbidity with autism spectrum
disorders (ASD) [5,6].
Recent evidence suggests that there is immune dysreg-
ulation in individuals with FXS that may play a role in
the disease process [7]. Neuroimmune interactions begin
during early neurodevelopment and continue through-
out life, with the immune system supporting many as-
pects of neural function. Alterations in the immune
system would increase sensitivity to neurologic damage
from a variety of sources including infection and expos-
ure to xenobiotics, particularly during early develop-
ment. Indeed, an increased frequency of infections has
been reported in a subgroup of boys with FXS, especially
in early childhood [8]. This may be the result of an aber-
rant or dysfunctional immune response in this group,
and possibly contributes to the frequently observed se-
vere cognitive deficit and language impairment [8]. Con-
sequently, there is a need for research that can identify
the biological basis of the immune anomalies in FXS,
which may facilitate future treatments.
Groundbreaking advances in the FXS field have paved
the way for treatment of the underlying neurobiology
of the disorder. The ‘mGluR theory’ of FXS, which is
strongly supported by several lines of evidence, states
that mental impairment and phenotypic behaviors asso-
ciated with FXS arise, at least in part, from constitutive
activation of translational pathways normally controlled
by group 1 metabotropic glutamate receptor (mGluR1
and mGluR5) activity [9]. Group I mGluRs are involved
in numerous functions including learning and memory,
and are expressed in both the central and peripheral ner-
vous system [10]. In neurons, mGluRs can augment syn-
apse excitability and thereby alter the function of other
receptors including GABA receptors [11].
mGluRs are expressed on peripheral blood mono-
nuclear cells (PBMC), where they are believed to be in-
volved in immune development, activation, response, and
survival [12-15]. mGluRs are members of the group C fam-
ily of G-protein-coupled receptors, and function by signal-
ing through G proteins to activate secondary messengers.They are responsive to low concentrations of glutamate,
such as that observed in the periphery, where glutamate
levels are typically between 20 to 40 μM in plasma [16];
considerably lower than what is found in synaptic clefs
within the central nervous system (CNS) where glutamate
levels can reach millimolar levels [17]. Group I mGluRs
in particular, are expressed differentially in naïve and
activated T-cells, with mGluR5 being constitutively
expressed and mGluR1 only being expressed in activated
T-cells [18]. In addition, mGluRs on T-cells have been
shown to be differentially coupled to intracellular signal-
ing systems such as cAMP, and ERK pathways [15]. It is
thought that the differential expression on the cell sur-
face and coupling to signaling mechanisms contributes to
T-cell activation, expression of pro-inflammatory cyto-
kines, and cell survival. In addition, mGluRs are also dif-
ferentially expressed on other immune cells such as
microglia and macrophages and may be related to activa-
tion status [19].
The present study focused on how group I mGluR ac-
tivation influences the immune response in pediatric
populations of typically developing (TD) children com-
pared to children with FXS, through an analysis of
dynamic immune cell function. To date, no study has
attempted to analyze the function of neurotransmitter re-
ceptors using PBMC in FXS. This study illustrates the
role of mGluRs in immune cell function in both a neuro-
typical pediatric population as well as in children with
FXS where mGluR signaling is altered, expanding upon
previous immunological findings in FXS.
Material and methods
Subjects
Twenty-seven male subjects with FXS aged 2 to 9 years
(median 5.4 years (interquartile range 3.7 to 7.5)) were
recruited through the Fragile X Treatment and Research
Center at the MIND Institute at University of California,
Davis, CA, USA. The study also included 8 male TD
controls aged 3 to 8 years (median 3.3 years (3.2 to
5.7 years)). Subjects on minocycline or other medica-
tions with established anti-inflammatory properties were
excluded from the study. All participants with FXS
underwent a clinical assessment that included a de-
tailed medical history and medical examination, and
measurements of typical genetic and physical features
of FXS. In addition, subjects underwent IQ testing and
adaptive skills testing using the following instruments: the
Wechsler Scales of Intelligence [20] and the Vineland
Adaptive Behavior Scales [21]. Controls were administered
a medical examination and the Social Communication
Questionnaire (SCQ) [22] to determine that they were
typically developing, and none exceeded scores above 15.
In addition, a review of available prenatal, birth, and
medical records were performed for all subjects. Clinical
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the supervision of one of the authors (RJH), a pediatrician
at the MIND Institute. The study protocol followed the
ethical guidelines of the declaration of Helsinki and was
approved by the Institutional Review Boards of the UC
Davis School of Medicine and the State of California, and
written informed consent was obtained from a legal guard-
ian for all study subjects.
CGG sizing
Genomic DNA was isolated from 3 to 5 mL of periph-
eral blood leukocytes using standard procedures (Gentra
Puregene kit; Qiagen, Valencia, CA). An initial centrifu-
gation step on whole blood permitted plasma separation
and storage before isolation of the DNA.
The size and methylation status of the CGG repeats
was determined using both Southern blot and PCR ana-
lysis. Details of the Southern blot and PCR methods are
in Tassone et al. [23] and Filipovic-Sadic et al. [24].
Analysis and calculation of the repeat size for both
Southern blot and PCR analysis was carried out using
an Alpha Innotech FluorChem 8800 Image Detection
System (ProteinSimple, Santa Clara, CA)and the ABI
3730XL 96-Capillary Electrophoresis Genetic Analyzer
(Life Technologies, Grand Island, NY).
Cell isolation
Peripheral blood was collected in an acid-citrate-dextrose
Vacutainer tube (BD Biosciences; San Jose, CA, USA)
and processed within 12 hours of collection. Blood was
centrifuged for 10 minutes at 2,300 rpm, and plasma
was collected and stored at −80°C. The remaining cells
were mixed 1:1 with Hanks Balanced Salt Solution
(HBSS; Gibco, Gaithersburg, MD, USA) without Ca2+
or Mg2+. The diluted blood was then carefully layered over
a Ficoll-Paque gradient (Pharmacia Biotech, Piscataway,
NJ, USA) and centrifuged at 1,700 rpm for 30 minutes at
room temperature. PBMC were then harvested from the
interface layer and washed twice with HBSS. Viability was
be determined by trypan blue exclusion. Cells were then
resuspended at a concentration of 2 × 106 cells/mL in tis-
sue culture medium (TCM) consisting of: RPMI 1640
(Gibco, Gaithersburg, MD, USA) supplemented with 10%
low endotoxin, heat inactivated FBS (Omega Scientific;
Tarzana, CA, USA), 100 IU/mL penicillin, and 100 IU/mL
streptomycin (Sigma, St Louis, MO, USA).
Cellular stimulations
Isolated PBMC were stimulated for one hour in RPMI
1640 media with 10% FBS (Gibco, Gaithersburg, MD,
USA), 1% penicillin and streptomycin alone, or the
addition of 100 μM of a group I mGluR agonist (S)-
3,5-dihydroxyphenylglycine (DHPG) (DHPG; Tocris,
Minneapolis, MN, USA), or 10 μM of an mGluR5 specificantagonist 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine
hydrochloride (MTEP; Tocris, Minneapolis, MN, USA)
followed by the addition of either 1.0 μg/mL lipopolysac-
charide (LPS; Escherichia coli serotype 0111:B4, Sigma,
St. Louis, MO, USA) or 8 μg/mL phytohemagglutinin
(PHA; Sigma, St Louis, MO, USA) and cultured at 37°C
with 5% CO2 for another 47 hours (48 hours total). After
this period, cells were collected and spun at 2,000 rpm
for 10 minutes and supernatants were collected and
stored at −80°C until analyzed by Luminex multiplexing
technology.
Luminex multiplex analysis
Quantification of IFNγ, granulocyte-macrophage colony-
stimulating factor (GM-CSF), IL-1β, IL-6, IL-10, IL-12
(p40), IL-13, IL-17 and TNFα in the cell supernatants
was determined using human multiplexing bead immu-
noassays (Millipore, Billerica, MA, USA). The cytokines
GM-CSF, IL-1β, IL-6, IL-10, TNFα, and IL-12(p40) were
used to evaluate innate immune responses after LPS
stimulation and the cytokines GM-CSF, IFNγ, IL-10,
IL-13, and IL-17 were used to assess responses after PHA
stimulation. Samples were analyzed per manufacturer
specifications. Specifically, 25 μL of supernatant were in-
cubated with antibody-coupled beads. After a series of
washes, a biotinylated detection antibody was added to
the beads, and the reaction mixture was detected by the
addition of streptavidin-phycoerythrin. The bead sets
were analyzed using a flow-based Luminex™ 100 suspen-
sion array system (Bio-Plex 200; Bio-Rad Laboratories,
Inc. Hercules, CA, USA). Unknown sample cytokine con-
centrations were calculated by Bio-Plex Manager soft-
ware (Bio-Rad Laboratories, Inc. Hercules, CA, USA)
using a standard curve derived from the known reference
cytokine concentrations supplied by the manufacturer.
A five-parameter model was used to calculate final con-
centrations and values are expressed in pg/mL. The
sensitivity of this assay allowed the detection of cyto-
kine concentrations with the following limits of detec-
tion: IFNγ (0.4 pg/mL), GM-CSF (2.3 pg/mL), IL-1β
(0.7 pg/mL), IL-6 (0.4 pg/mL), IL-10 (0.3 pg/mL), IL-12
(p40) (12.3 pg/mL), IL-13 (0.3 pg/mL), IL-17 (0.4 pg/mL),
and TNFα (0.2 pg/mL). Values below the limit of detection
(LOD) were replaced with one half the LOD. Supernatant
aliquots were free of any previous freeze/thaw cycle.
Statistical analysis
Data analysis was performed using STATA 12 software
(College Station, TX, USA). Data was determined as
non-parametric using Shapiro-Wilks test for normality.
Wilcoxon matched-pairs signed-rank tests were used to
compare cytokine levels within group pre and post
stimulation and Wilcoxon-rank sum tests for between
subject group comparisons. For comparison of relative
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mined if datum were greater than four median absolute
deviations from the mean. A probability value (P) of less
than 0.05 was considered to be significant.
Results
PBMC from children with FXS and TD controls were
stimulated with LPS, a Toll-like receptor (TLR)-4 agon-
ist, for 48 hours to assess the dynamic response of their
innate immune system. No significant differences were
apparent in the supernatants collected from the cell cul-
tures of TD controls compared with children with FXS
in the cytokines assayed (GM-CSF, IL-1β, IL-6, IL-10,
TNFα, and IL-12(p40)) (Table 1). When a group I mGluR
agonist, DHPG, was added during stimulation there was
a significant decrease in cytokines levels for GM-CSF
(P = 0.04), IL-12(p40) (P = 0.01), and TNFα (P = 0.03) in
TD controls (Table 1). In contrast, cell culture superna-
tants from children with FXS showed that select inflam-
matory cytokines levels were increased or remained
unchanged after administration of DHPG to the culture
(P < 0.01; Table 1). Further, the anti-inflammatory cyto-
kine, IL-10, was decreased following stimulation in the
presence of DHPG (P < 0.01; Table 1). The exception to
these findings was IL-1β production, which was margin-
ally increased in TD controls (P = 0.05) but still had a
greater production in FXS children, with an over two-
fold increase (P < 0.01) when PBMC were stimulated with
LPS plus DHPG (Table 1).
Overall, the apparent skewing in cytokine production
could be observed as a differential response to LPS
stimulation in the presence of DHPG compared with
LPS alone (Figure 1A-D); such that TD controls displayed
a significantly lower production of IL-6 (median −17.3%
(interquartile range −33.0 to −0.4%) versus 11.4% (−11.7
to 43.6%); P = 0.02) and IL-12(p40) (median −48.7%
(interquartile range −69.7 to −19.8%) versus 0% (−21.1
to 43.4%); P < 0.01) in the presence of DHPG com-
pared with children with FXS. In addition, both TNFα
(median −15.5% (interquartile range −30.8 to −4.8%)Table 1 Cytokine levels in lipopolysaccharide (LPS)-stimulated
TD
Cytokine LPS LPS + DHPG P-val
GM-CSF 50.4 (27.9 to 58.9) 39.6 (19.5 to 42.9) 0.04
IL-1β 1,245.3 (957.4 to 1,855.5) 1,567.6 (1,160.2 to 2,235.0) 0.05
IL-6 3,203.9 (2,043.8 to 5,14.0) 2,856.1 (1,701.6 to 4,715.8) 0.33
IL-10 271.2 (106.3 to 765.6) 100.0 (85.0 to 515.8) 0.40
IL-12(p40) 59.2 (36.9 to 72.5) 24.1 (16.3 to 51.2) 0.01
TNFα 838.4 (626.3 to 1,034.4) 570.7 (485.1 to 914.5) 0.03
Values reported as median (interquartile range) in pg/mL. All P-values were calculat
(S)-3,5-dihydroxyphenylglycine; FXS, fragile X syndrome; TD, typically developing.versus −1.6% (−18.3 to 25.8); P = 0.07) and GM-CSF
(median −19.9% (interquartile range −28.0 to −1.7%) ver-
sus 6.7% (−23.5 to 33.8%); P = 0.11) showed trends toward
a higher differential response in TD controls compared
children with FXS approaching statistical significance.
To determine if the basal level of glutamate in the cul-
ture media was altering baseline response of PBMC via a
group I mGluR-dependent manner in children with FXS,
a group I mGluR antagonist, MTEP, was added to the
culture during LPS stimulation (Figure 2A-D). In TD
controls, cytokine responses tended to be higher with sig-
nificantly increased production of both IL-1β (P = 0.03)
and IL-10 (P = 0.04) detected (Table 2), as anticipated,
largely having the opposite trend as was seen with the
group mGluR agonist DHPG. Children with FXS also
tended to show increased responses, with elevated levels
of IL-1β (P < 0.01), IL-6 (P < 0.01), and IL-10 (P < 0.01).
However, the production of GM-CSF was significantly de-
creased (P < 0.01) under these conditions (Table 2). When
the relative response to LPS and MTEP to LPS alone was
compared between TD controls and children with FXS,
GM-CSF ((−16.1% (−16.5 to 8.7%) versus −44.3% (−54.4
to −35.6%); P = 0.02) responses were reduced significantly
more in children with FXS.
The adaptive immune responses were compared be-
tween TD controls and children with FXS by measuring
cytokine production after culturing PBMC with a cellu-
lar mitogen, PHA, which preferentially activates T-cells.
No significance differences were apparent between the
two groups (Table 3). Further, the addition of DHPG to
the PHA cultures did not alter the cytokine production
in TD controls. However, a significant decrease in TH2
associated cytokines IL-10 (P < 0.01) and IL-13 (P = 0.01)
was observed in children with FXS versus the TD con-
trols (Table 3). Unlike the innate response, no significant
differential response between PHA and DHPG relative
to PHA alone was apparent between groups (data not
shown). The addition of MTEP to the PHA cultures
resulted in a moderate but not significant increase in
IL-10 production (P > 0.05) in TD controls. In childrenand LPS plus DHPG-stimulated cell cultures
FXS
ue LPS LPS + DHPG P-value
a 45.2 (17.7 to 70.7) 55.3 (20.1 to 107.2) 0.28
a 1,146.0 (607.9 to 1,748.2) 2,326.9 (952.6 to 3,313.6) < 0.01b
2,900.2 (1,792.2 to 5,110.3) 4,366.9 (2,047.0 to 6,251.1) 0.21
286.8 (184.0 to 573.0) 179.3 (76.3 to 342.1) 0.01b
a 25.0 (6.2 to 77.3) 46.1 (15.1 to 91.0) 0.37
a 724.2 (413.0 to 1,381.2) 1,010.4 (458.1 to 1,510.4) 0.49
ed by Wilcoxon matched-pair signed-rank test. aP < 0.05; bP < 0.01. DHPG,
* **
DHPG - IL-12(p40)DHPG - IL-6
DHPG - TNF
A
C
B
DHPG - GM-CSFD
Figure 1 Peripheral blood mononuclear cells’ (PBMC) response to lipopolysaccharide (LPS) stimulation with a group I mGluR agonist.
PBMC from children with fragile X syndrome (FXS) displayed an opposite or exaggerated immune response to LPS and (S)-3,5-dihydroxyphenylglycine
(DHPG) relative to LPS alone when compared with typically developing (TD) controls for (A) IL-6 (P = 0.02), (B) IL-12(p40) (P < 0.01), and similar albeit
non-significant trends for both (C) TNFα (P = 0.07) and (D) GM-CSF (P = 0.11). *P < 0.05, **P < 0.01.
MTEP - IL-1
MTEP - IL-10
MTEP - GM-CSF
MTEP - IL-6
A B
C D
**
Figure 2 Peripheral blood mononuclear cells’ (PBMC) response to lipopolysaccharide (LPS) stimulation with a mGluR5 antagonist.
PBMC from children with fragile X syndrome (FXS) displayed an opposite immune response to LPS and 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine
hydrochloride (MTEP) relative to LPS alone when compared with typically developing (TD) controls for (A) GM-CSF (P < 0.01). (B) IL-1β,
(C) IL-6, and (D) IL-10 showed similar responses to MTEP in both subjects and controls. *P < 0.05, **P < 0.01.
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Table 2 Cytokine levels in lipopolysaccharide (LPS)-stimulated and LPS plus MTEP-stimulated cell cultures
TD FXS
Cytokine LPS LPS +MTEP P-value LPS LPS +MTEP P-value
GM-CSF 50.4 (27.9 to 58.9) 39.8 (36.5 to 49.4) 0.35 45.2 (17.7 to 70.7) 25.5 (11.7 to 57.6) < 0.01b
IL-1β 1,245.3 (957.4 to 1,855.5) 1,545.9 (972.5 to 2,312.1) 0.03a 1,146.0 (607.9 to 1,748.2) 1,558.4 (883.3 to 2,148.6) < 0.01b
IL-6 3,203.9 (2,043.8 to 4,514.0) 4,195.3 (2,235.9 to 6,071.8) 0.12 2,900.2 (1,792.2 to 5,110.3) 3,969.3 (2,352.4 to 7,203.9) 0.01a
IL-10 271.2 (106.3 to 765.6) 415.6 (168.7 to 1,076.6) 0.03a 286.8 (184.0 to 573.0) 389.2 (210.4 to 608.2) < 0.01b
IL-12(p40) 59.2 (36.9 to 72.5) 89.8 (17.3 to 101.8) 0.53 25.0 (6.2 to 77.3) 43.7 (22.5 to 96.3) 0.44
TNFα 838.4 (626.3 to 1,034.4) 922.5 (531.7 to 1,190.7) 0.75 724.2 (413.0 to 1,381.2) 925.1 (516.7 to 1,557.1) 0.93
Values reported as median (interquartile range) in pg/mL. All P-values were calculated by Wilcoxon matched-pair signed-rank test. aP < 0.05; bP < 0.01. FXS, fragile
X syndrome; MTEP, 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine hydrochloride; TD, typically developing.
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with significantly lower levels of GM-CSF (P < 0.01), and
lower (not significant) levels of IL-13 (P = 0.12) (Table 4).
Discussion
Systemic immune differences have previously been noted
in children with FXS compared with TD controls [7].
This included increased IL-1α, as well as decreased
RANTES and IP-10 in plasma. In addition, increased
rates of infection have been observed in children with
FXS, suggesting that immune dysregulation or non-
optimal immune function may occur in these children
leading to increased susceptibility to infection [8]. How-
ever, it is not clear if this immune dysfunction results from
differences in the cellular immune response following im-
mune challenge, or from other physiological factors. In
this study we found that peripheral blood immune cells
from children with FXS respond to LPS and PHA in a
similar fashion as cells from TD children. This suggest
that differences in plasma cytokine values previously ob-
served could result from other physiological stresses ob-
served in FXS, particularly increased anxiety, as anxiety
levels have been shown to relate to inflammation in a
number of studies [25]. Alternatively, immune differences
might be restricted to specific anatomical compartments,
such as the gastrointestinal tract or liver, which can affect
circulating levels of cytokines while analysis of circulatingTable 3 Cytokine levels in phytohemagglutinin (PHA)-stimula
TD
Cytokine PHA PHA + DHPG P-va
GM-CSF 8.4 (2.3 to 76.9) 9.6 (4.6 to 45.1) 0.3
IFNγ 9.3 (5.3 to 122.1) 9.9 (5.1 to 113.0) 0.7
IL-10 40.3 (17.7 to 144.3) 34.2 (25.5 to 117.5) 1.0
IL-13 6.2 (3.4 to 135.9) 7.4 (3.1 to 82.4) 0.0
IL-17 15.4 (6.5 to 70.1) 15.4 (6.9 to 40.2) 0.7
Values reported as median (interquartile range) in pg/mL. All P-values were ca
(S)-3,5-dihydroxyphenylglycine; FXS, fragile X syndrome; TD, typically developiimmune cells may not adequately reflect immune differ-
ences at these sites.
Group I mGluRs have also been implicated in the
pathogenesis of FXS [26]. In FXS, the decreased produc-
tion of FMRP is thought to lead to a lack of dampening
of group I mGluR signaling, resulting in aberrant activa-
tion of these receptors. Down-regulation of group I
mGluRs in a mouse model of FXS has demonstrated that
this is sufficient to ameliorate most of pathological effects
seen in FXS [27], suggesting group I mGluRs are highly
involved in the pathogenesis of FXS. Although it is diffi-
cult, if not impossible, to assess mGluR function in the
CNS of children, their peripheral expression (including
most immune cells) provides a novel opportunity to as-
sess mGluR function in a non-invasive way. Utilizing this
alternative source of mGluRs, we sought to determine if
group I mGluR signaling could be assessed in subjects
by taking advantage of the known ability of mGluRs to
modulate the immune system [13,28]. Given the pur-
ported mGluR expression and signaling differences in
FXS, we hypothesized that analysis of mGluR in the con-
text of immune stimulation could help to explain immune
differences previously seen in the periphery in subjects
with FXS.
In the presence of the group I mGluR agonist, DHPG,
activation of the innate immune system demonstrated
that TD controls generally showed a decrease in cytokineted and PHA plus DHPG-stimulated cell cultures
FXS
lue PHA PHA + DHPG P-value
6 11.0 (4.2 to 32.7) 8.2 (5.2 to 25.8) 0.81
2 8.6 (3.0 to 113.2) 5.6 (1.3 to 221.9) 0.89
0 44.0 (16.5 to 115.0) 26.9 (15.3 to 74.6) < 0.01b
9 6.1 (0.2 to 22.1) 2.6 (0.2 to 18.8) < 0.01b
3 18.0 (2.7 to 43.6) 12.1 (5.1 to 34.3) 0.18
lculated by Wilcoxon matched-pair signed-rank test. bP < 0.01. DHPG,
ng.
Table 4 Cytokine levels in phytohemagglutinin (PHA)-stimulated and PHA plus MTEP-stimulated cell cultures
TD FXS
Cytokine PHA PHA +MTEP P-value PHA PHA +MTEP P-value
GM-CSF 8.4 (2.3 to 76.9) 3.7 (2.6 to 14.5) 0.83 11.0 (4.2 to 32.7) 3.5 (1.2 to 12.1) 0.01a
IFNγ 9.3 (5.3 to 122.1) 4.4 (1.4 to 14.4) 0.83 8.6 (3.0 to 113.2) 1.5 (1.3 to 8.6) 0.23
IL-10 40.3 (17.7 to 144.3) 34.0 (29.4 to 60.8) 0.05 44.0 (16.5 to 115.0) 40.4 (9.3 to 67.7) 0.46
IL-13 6.2 (3.4 to 135.9) 8.1 (2.7 to 29.1) 0.67 6.1 (0.2 to 22.1) 0.2 (0.2 to 9.6) 0.12
IL-17 15.4 (6.5 to 70.1) 12.6 (6.5 to 35.6) 0.25 18.0 (2.7 to 43.6) 5.9 (0.9 to 20.2) 0.69
Values reported as median (interquartile range) in pg/mL. All P-values were calculated by Wilcoxon matched-pair signed-rank test. aP < 0.05. FXS, fragile X syndrome;
MTEP, 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine hydrochloride; TD, typically developing.
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sponse of microglia following administration of DHPG
where a decrease the inflammatory response to LPS has
been noted [29]. The activation of mGluR5 has also been
shown to reduce microglial associated inflammation and
neurotoxicity [30]. Thus, PBMC from TD controls respond
to DHPG in a manner similar to central myeloid cells, that
is decreased inflammatory cytokine response in the pres-
ence of immune challenge. However, immune cells from
children with FXS when exposed to DHPG in the presence
of LPS did not show the same level of inhibition of inflam-
mation as the TD controls. In the CNS, glutamate serves
many purposes, including acting as a messenger between
neurons and microglia, and it has also been shown that
glutamate signaling in microglia could serve a protective
role [31]. Therefore, dysregulation of group I mGluR-
mediated inhibition in microglia would have potentially
devastating effects and lead to negative outcomes such as
reduced immune regulation with an increase in neuroin-
flammation. Agents known to reduce neuroinflammation,
such as the tetracycline derivative minocycline, have been
shown to rescue many of the impairments seen in the
FMR1 knockout (KO) mouse when administered during
early development [32]. The observed pattern of immune
dysregulation following LPS coupled with DHPG in our
study would also explain previous observations in the
FMR1 KO mouse. When LPS was given to FMR1 KO
mice, similar peripheral immune responses were seen in
comparison to wild-type (WT) controls, with the KO mice
demonstrating both normal peripheral immune responses
and normal microglia responses in culture. However, iso-
lates from the brains of these animals, where glutamate
levels would be the highest, showed signs of immune acti-
vation and neuroinflammation [33].
The addition of DHPG to PHA-stimulated cell cul-
tures resulted in similar levels of cytokine production
between children with FXS and controls. In general, re-
sults were much more variable than in the LPS cultures.
As PHA preferentially activates T-cells, this might relate
to previous findings regarding the ability of mGluRs
to regulate T-cell immunity. Not only are mGluR1 andmGluR5 differentially coupled to separate signaling sys-
tems in lymphocytes, their surface expression differs de-
pending on the state of the cell. Immature T-cells show
little or no mGluR1 expression unlike mature T-cells, and
mGluR5 seems to be constitutively expressed by these
cells [15,18]. As both the phosphatidylinositide 3-kinase
(PI3K) and mitogen-activated protein kinase (MAPK)
pathways have been suggested to be dysregulated in FXS
[34,35], and as these pathways are involved in T-cell mat-
uration and survival [36], altered mGluR expression may
be masking the difference in mGluR function in T-cells.
Blocking of group I mGluR through pharmaceutical
means has proven to be beneficial in animal models of
FXS. In mouse models of FXS, administration of the
group I mGluR antagonists, 2-methyl-6-(phenylethynyl)
pyridine hydrochloride (MPEP), has been shown to re-
verse a number of phenotypes including autogenic sei-
zures and abnormal open field exploration [37], deficits
in prepulse inhibition [38], decreased mRNA granule ex-
pression [39], excess protein in hippocampal slices [40],
and increased density of dendritic filopodia in hippo-
campal cultures [38]. In our study, administration of
MTEP to the immune cell cultures stimulated with LPS
resulted in lower production of GM-CSF in children
with FXS compared with TD controls. Although MTEP
is more specific than MPEP for the mGluRs, it has a
short half-life and might not have been fully effective in
suppressing all mGluR5 for the duration of the stimula-
tion used herein [41]. Several newer inhibitors are in
production and might better serve as agents to test the
role mGluR antagonist on dynamic immune response.
Although it is not fully known how mGluRs regulate
the immune response, many of the pathways mGluRs
signal through are convergent with signaling pathways
utilized by immune cell receptors. Immune cells sense
LPS though TLR4, a pathogen-associated molecular pat-
tern (PAMP) receptor, which leads to a signaling cascade
and the activation of the nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB) and the MAPK path-
ways. The activation of these pathways culminates in the
activation of transcription factors, which in turn promote
Figure 3 Group I mGluR-signaling pathway in immune cells. Activation of pathogen associated molecular pattern (PAMP) receptors leads to
a signaling cascade which can be both inhibited and assisted by group I mGluR signaling.
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anti-inflammatory cytokines. Group I mGluRs can inhibit
or assist these pathways. Although not fully characterized
in myeloid cells, in lymphocytes mGluR1 is coupled to Gαq
and activates the phospholipase C (PLC), PI3K, and MAPK
pathways [18]. mGluR5, however, preferentially couples to
Gαs, which activates the adenylyl cyclase and leads to the
production of the secondary messenger 3’,5’-cyclic AMP
(cAMP) [18]. Whereas mGluR1 pathways tend to assist
PAMP signaling, mGluR5 inhibits through the production
of cAMP (Figure 3). In FXS, cAMP tends to be lower and
cAMP metabolism has been shown to be dysregulated
[42-44]. This dysregulation of the cAMP system might be
hindering the effects of mGluR5 in myeloid cells in chil-
dren with FXS, leading to a lack of inhibition of cytokine
production when stimulated. This altered response to glu-
tamate by mGluR could have dire effects of the ability of
the immune system in the CNS to regulate immune
homeostasis, and could have implications into the path-
ology of FXS.
Conclusion
Children with FXS did not display an altered dynamic
immune response to LPS at a cellular level; however,
subjects with FXS showed an altered response to LPS withDHPG, leading to increased production of inflammatory
cytokines. Stimulation of immune cells from subjects with
FXS with PHA or PHA with DHPG resulted in no differ-
ence in cytokine production in immune cells from similarly
treated TD controls. In addition, this study demonstrates
that group I mGluR functionality can be tested using a sur-
rogate cellular system instead of neurons. These findings
should be valuable in the generation of testable hypothesis
to understand how immune and mGluR activation can in-
fluence neuronal dysfunction and alter patterns of early
brain development in FXS. In addition, mGluR function in
PBMC could help to better establish efficacy of drug stud-
ies utilizing mGluR-modulating agents.Abbreviations
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